BIO icon

Bio-Rad Laboratories Class A

231.70 USD
+4.79
2.11%
At close Jun 16, 4:00 PM EDT
After hours
231.70
+0.00
0.00%
1 day
2.11%
5 days
1.78%
1 month
-6.82%
3 months
-9.84%
6 months
-32.44%
Year to date
-28.96%
1 year
-21.66%
5 years
-49.08%
10 years
56.07%
 

About: Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Employees: 7,700

0
Funds holding %
of 7,299 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

2.25% more ownership

Funds ownership: 81.88% [Q4 2024] → 84.13% (+2.25%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 4 (+0) [Q1 2025]

4% less call options, than puts

Call options by funds: $3.6M | Put options by funds: $3.77M

6% less funds holding

Funds holding: 445 [Q4 2024] → 420 (-25) [Q1 2025]

18% less repeat investments, than reductions

Existing positions increased: 132 | Existing positions reduced: 160

20% less first-time investments, than exits

New positions opened: 68 | Existing positions closed: 85

24% less capital invested

Capital invested by funds: $6.17B [Q4 2024] → $4.67B (-$1.49B) [Q1 2025]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$245
6%
upside
Avg. target
$324
40%
upside
High target
$392
69%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
Wells Fargo
Brandon Couillard
6%upside
$245
Equal-Weight
Maintained
9 Jun 2025
UBS
Dan Leonard
34%upside
$310
Buy
Maintained
2 May 2025
Citigroup
Patrick Donnelly
51%upside
$350
Buy
Maintained
2 May 2025
RBC Capital
Conor McNamara
69%upside
$392
Outperform
Maintained
2 May 2025

Financial journalist opinion

Neutral
Business Wire
2 weeks ago
Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Operating Officer Jon DiVincenzo will host one-on-one meetings with investors during the Jefferies Global Healthcare Conference in New York City, on June 4, 2025. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range o.
Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference
Neutral
Zacks Investment Research
1 month ago
Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends
Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends
Neutral
Business Wire
1 month ago
Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 1:35 PM Eastern Time (10:35 AM Pacific Time). A live webcast and subsequent replay of the.
Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference
Neutral
Zacks Investment Research
1 month ago
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket
Bio-Rad witnesses first-quarter top-line decline in its Life Science segment, primarily due to challenges in the academic research market.
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket
Neutral
Seeking Alpha
1 month ago
Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2025 Earnings Conference Call May 1, 2025 5:30 PM ET Company Participants Edward Chung - Head of Investor Relations Jon DiVincenzo - President and Chief Operating Officer Roop Lakkaraju - Executive Vice President and Chief Financial Officer Norman Schwartz - Chief Executive Officer Conference Call Participants Patrick Donnelly - Citigroup Dan Leonard - UBS Brandon Couillard - Wells Fargo Conor McNamara - RBC Capital Markets Jack Meehan - Nephron Research Operator Ladies and gentlemen, thank you for standing by. My name is Desyree, and I will be your conference operator today.
Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.54 per share, beating the Zacks Consensus Estimate of $1.73 per share. This compares to earnings of $2.29 per share a year ago.
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
Neutral
Business Wire
1 month ago
Bio-Rad Reports First-Quarter 2025 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2025. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: “We navigated a highly dynamic first quarter that became progressively more challenging, yet we delivered solid margins through focused execution and careful expense management. Given the.
Bio-Rad Reports First-Quarter 2025 Financial Results
Negative
Zacks Investment Research
1 month ago
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Positive
Zacks Investment Research
2 months ago
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
BIO continues to attract investors' attention due to its robust performance in the ddPCR platform.
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
Neutral
MCAP MediaWire
2 months ago
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
IRVINE, Calif., March 24, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow Shareholders, Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring test kit to the market next year.
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
Charts implemented using Lightweight Charts™